Vetoquinol (VETO) - Total Assets
Based on the latest financial reports, Vetoquinol (VETO) holds total assets worth €725.82 Million EUR (≈ $848.56 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VETO debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Vetoquinol - Total Assets Trend (2004–2024)
This chart illustrates how Vetoquinol's total assets have evolved over time, based on quarterly financial data. See VETO net assets for net asset value and shareholders' equity analysis.
Vetoquinol - Asset Composition Analysis
Current Asset Composition (December 2024)
Vetoquinol's total assets of €725.82 Million consist of 56.6% current assets and 43.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.00K | 27.7% |
| Accounts Receivable | €92.56 Million | 12.4% |
| Inventory | €112.29 Million | 15.1% |
| Property, Plant & Equipment | €92.60 Million | 12.4% |
| Intangible Assets | €142.09 Million | 19.1% |
| Goodwill | €76.41 Million | 10.3% |
Asset Composition Trend (2004–2024)
This chart illustrates how Vetoquinol's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Vetoquinol worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vetoquinol's current assets represent 56.6% of total assets in 2024, an increase from 0.0% in 2004.
- Cash Position: Cash and equivalents constituted 27.7% of total assets in 2024, up from 7.7% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, a decrease from 31.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 19.1% of total assets.
Vetoquinol Competitors by Total Assets
Key competitors of Vetoquinol based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.03 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $36.83 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Humanwell Healthcare Group Co Ltd
SHG:600079
|
China | CN¥37.56 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Vetoquinol - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 2.76 | 2.73 |
| Quick Ratio | 2.13 | 1.91 | 1.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €282.00 Million | €244.67 Million | €173.20 Million |
Vetoquinol - Advanced Valuation Insights
This section examines the relationship between Vetoquinol's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.83 |
| Latest Market Cap to Assets Ratio | 1.33 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | €744.13 Million |
| Market Capitalization | $987.70 Million USD |
Valuation Analysis
Above Book Valuation: The market values Vetoquinol's assets above their book value (1.33x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Vetoquinol's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Vetoquinol (2004–2024)
The table below shows the annual total assets of Vetoquinol from 2004 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €744.13 Million ≈ $869.97 Million |
+7.50% |
| 2023-12-31 | €692.23 Million ≈ $809.29 Million |
+6.20% |
| 2022-12-31 | €651.85 Million ≈ $762.08 Million |
+4.37% |
| 2021-12-31 | €624.56 Million ≈ $730.18 Million |
-3.33% |
| 2020-12-31 | €646.09 Million ≈ $755.35 Million |
+26.32% |
| 2019-12-31 | €511.47 Million ≈ $597.96 Million |
+9.86% |
| 2018-12-31 | €465.58 Million ≈ $544.32 Million |
+4.87% |
| 2017-12-31 | €443.97 Million ≈ $519.05 Million |
+1.09% |
| 2016-12-31 | €439.17 Million ≈ $513.44 Million |
+6.47% |
| 2015-12-31 | €412.48 Million ≈ $482.23 Million |
-1.64% |
| 2014-12-31 | €419.36 Million ≈ $490.28 Million |
+19.19% |
| 2013-12-31 | €351.83 Million ≈ $411.33 Million |
-1.29% |
| 2012-12-31 | €356.44 Million ≈ $416.71 Million |
+11.98% |
| 2011-12-31 | €318.31 Million ≈ $372.14 Million |
+2.86% |
| 2010-12-31 | €309.45 Million ≈ $361.78 Million |
+9.09% |
| 2009-12-31 | €283.67 Million ≈ $331.64 Million |
+19.98% |
| 2008-12-31 | €236.43 Million ≈ $276.41 Million |
+3.51% |
| 2007-12-31 | €228.41 Million ≈ $267.03 Million |
+8.44% |
| 2006-12-31 | €210.62 Million ≈ $246.24 Million |
+5.46% |
| 2005-12-31 | €199.72 Million ≈ $233.49 Million |
+12.86% |
| 2004-12-31 | €176.96 Million ≈ $206.89 Million |
-- |
About Vetoquinol
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal … Read more